CAS: 1449-05-4; Glycyrrhetinate

该化合物是一种来自甘基里希津的三叶虫类化合物,产自甘醇植物(Glycyrrhiza glabra)的根部,其特征为五环形结构,包括环球开球氢酚酚苯乙烯核心,该化合物展示了一系列生物活动,包括抗炎,抗病毒和肝脏保护特性,这使它对药理学研究感兴趣,经常研究其在肝脏疾病和病毒感染等条件下的潜在治疗作用. 18-伽利略酸也众所周知,抑制了酶11-氢氧素脱氢酶2型,这可能影响浮质代谢,并影响与甲状腺激素调控有关的条件.就溶解而言,它一般在有机溶剂中比在水中更容易溶解,从而影响其生物利用率和在配方中的应用.

结构式图片

欧盟法规

ECHA物质C&L通报REACH预注册

上下游产品

enoxolone methyl 3-benzoyl-18α-glycyrrhetinate glycyrrhetic acid 3-O-mono-β-D-glucuronide 3-oxo-18β-glycyrrhetinic acid Glycyrrhetinsaeure-β-D-glucopyranosylester Glycyrrhetinsaeure-methylester (3β,18α,20β)-3-hydroxy-11-oxoolean-12-en-29-oic acid diphenylmethyl ester

合成工艺路线路线简述

    📜甘草次酸置于氢氧化钾体系中,用 二乙二醇 用作溶剂,化学反应 2.0H,以45%的收率获得18α-甘草次酸
    参考文献:甘草次酸衍生物的乳糖苷的合成及溶血性能
    标题:甘草次酸衍生物的乳糖苷的合成及溶血性能
    摘要:描述了甘草次酸,其11-脱氧和18α-衍生物及其甲基酯的乳糖苷的部分合成.糖苷配基结构对标题化合物溶血特性的影响进行了讨论,并与齐墩果酸衍生物进行了比较.此外,我们描述了18α-甘草次酸的优化制备方法.
    Doi:10.1007/s706-002-8243-6

    海关参考信息

    专利信息


    专利号:US-2019029993-A1
    优先权日:2017-07-26
    标 题 :Quality of life extension therapies relating to aging, food allergies, pain and reduced vigor by managing molecular, cellular and subcellular biochemical requirements of mitochondria and other organelle processes
    发明人:POSTREL RICHARD
    权利人:POSTREL RICHARD
    摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.

    专利号:US-2019030044-A1
    优先权日:2017-07-26
    标 题:Human life extension therapy through molecular, cellular and subcellular management of biochemical requirements of mitochondria and of other organelle processes associated with the advent of disease and/or aging
    发明人:POSTREL RICHARD
    权利人:POSTREL RICHARD
    摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as a human continues to age, rebalancing the organism's metabolism through providing mitochondrial supplements, and serially revisiting effects of the early stages of treatment to redirect or improve activity of all aspects of life and metabolism.

    专利号:US-9575067-B2
    优先权日:2007-05-23
    标 题 :Polymeric carriers for immunohistochemistry and in situ hybridization
    发明人:KOSMEDER II JERRY W; KERNAG CASEY A; JOHNSON DONALD; BIENIARZ CHRISTOPHER
    权利人:VENTANA MED SYST INC
    摘要:Certain disclosed embodiments of the present invention concern the synthesis, derivatization, conjugation to immunoglobulins and signal amplification based on discrete, relatively short polymers having plural reactive functional groups that react with plural molecules of interest. Reactive functional groups, such as hydrazides, may be derivatized with a variety of detectable labels, particularly haptens. The remaining reactive functional groups may be conjugated directly to a specific binding molecule, such as to the oxidized carbohydrate of the Fc region of the antibody. Disclosed conjugates display large signal amplification as compared to those based on molecules derivatized with single haptens, and are useful for assay methods, particularly multiplexed assays.

    专利号:US-2020078333-A1
    优先权日:2016-12-21
    标 题 :Healthier Aging in Domesticated Animals
    发明人:POSTREL RICHARD
    权利人:POSTREL RICHARD
    摘要:This invention provides compositions, systems and methods that improve and/or optimize the health and performance of animals, especially mammals including humans, canines, equines, felines, etc. Key aspects of the principle invention and its parts include the monitoring, management and modulation of the body's natural cannabinoid systems through its native mechanisms thereby optimizing its processes by supplementation with endogenously occurring components and/or by administering synthetic compounds. The invention selects from multiple available resources to modify and/or rebalance an individual system or it may be applied across interconnected systems. The encompassing system that is intricately involved in the operations and intensities, e.g., the balancing of most other systems of our bodies, relates to cannabinoid compounds and their receptors. The cannabinoid pathways can be coordinated in rebalancing multiple and various metabolic pathways. Compositions comprising compounds that slow degradation of native endocannabinoids, that stimulate their production and/or compounds that act on cannabinoid receptors within the body are featured in systems and methods of this invention. The activated and rebalanced cannabinoid systems then become adept at modulating and the rebalancing of the numerous systems in which they participate to improve one or more systems including, but not limited to: normal and/or abnormal stresses of life, environmental influences, genomic or epigenomic irregularities and/or normal or accentuated processes of aging. Specifically targeted systems may include, but are not limited to, those involved in: cellular and/or mitochondrial metabolism, corticosteroid synthesis and effects, appetite, allergy and immunity, sleep and waking, etc. Practicing the invention selects from multiple approaches that may be used independently or in concert to compensate for a variety of concerns. Supplementing dietary intake to rebalance metabolism and/or its metabolic responses—including immunogenic or allergic responses to pathogenic and/or environmental stresses is one focus. Additional features of the invention may include: compensating for failing or decreasing androgen hormone levels as an animal continues to age, rebalancing the organism's m

    专利号:CN-115490746-B
    优先权日:2021-06-17
    标题:A microwave-assisted synthesis method of 18α-glycyrrhetinic acid and its derivatives

    专利号:CN-115490746-A
    优先权日:2021-06-17
    标题 :Microwave-assisted synthesis method of 18 alpha-glycyrrhetinic acid and derivatives thereof

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    合成参考文献


    参考文献:10.1111/j.0105-1873.2006.0645i.x
    摘要:Oiso N, Ota T, Yoshinaga E, Endo H, Kawara S, Kawada A. Allergic contact dermatitis mimicking atopic dermatitis due to enoxolone in a topical medicament. Contact Dermatitis. 2006 Jun;54(6):351. doi: 10.1111/j.0105-1873.2006.0645i.x.
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知